Inclusion Criteria:

          -  18 to 75 years with a weight ≥ 40 kg

          -  Patients must have signed informed consent

          -  Patients with stage IIIb, IIIc or IV metastatic melanoma (AJCC 6th edition) with at
             least two lesions (lymph nodes relapse, or in transit metastasis, or unresectable
             cutaneous metastases, or visceral metastases except bone and brain metastases)
             including one easily accessible and no more than 2 lines of treatment of melanoma at
             the metastatic stage.

          -  Patients with a melanoma expressing a Braf V600 mutation can be included only in case
             of targeted biotherapy (BRAF inhibitor +/- mitogen-activated protein kinase kinase
             enzymes (MEK) inhibitor) failure

          -  Measurable/assessable disease in 28 days which precede the first administration of the
             treatment

          -  A negative pregnancy test for women with childbearing potential

          -  Eastern Cooperative Oncology Group (ECOG) of 0-1, Karnofsky > 80%

          -  Laboratory results:

        Haemoglobin ≥ 10 g/dl or ≥ 6,25 mmol/l; Neutrophils ≥ 1500/μl; Leukocytes ≥ 4000/μl;
        Lymphocytes ≥ 700/μl; Blood platelet ≥ 100.000/μl; Serum creatinine ≤ 1.5 x superior normal
        value or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula);
        Serum bilirubin ≤ 2.0 mg/dl or ≤ 34.2 mol/l; Total bilirubin ≤ 1.5 x superior normal value
        (except subjects with Gilbert Syndrome, who can have total bilirubin < 3mg/dL); Aspartate
        aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2 x superior normal value;
        Lactate dehydrogenase (LDH) ≤ 1.5 x superior normal value

          -  Subjects affiliated to an appropriate health insurance

          -  Women of childbearing potential (WOCBP) must use appropriate method(s) of
             contraception during the clinical trial. Furthermore WOCBP will be instructed to
             adhere to contraception for a period of 5 months after the last dose of Nivolumab.

          -  Men who are sexually active with WOCBP will be instructed to adhere to contraception
             during the clinical trial and for a period of 7 months after the last dose of
             Nivolumab.

          -  Women who are not of childbearing potential (ie, who are postmenopausal or surgically
             sterile) as well as azoospermic men do not require contraception.

        Non inclusion Criteria:

          -  Brain or bone metastases

          -  Ocular melanoma

          -  Chemotherapy or radiotherapy within 4 weeks before baseline (6 weeks for nitroso-ureas
             and mitomycin C)

          -  Contraindication for the use of vasopressor agents

          -  For female: the patient is pregnant or breastfeeding or not using contraception

          -  For men: the patient is sexually active with WOCBP and not using contraception

          -  History or current manifestations of severe progressive heart disease (congestive
             heart failure, coronary artery disease, uncontrolled arterial hypertension, serious
             rhythm disorders or ECG signs of previous myocardial infarction)

          -  Patients should be excluded if they have had prior treatment with an anti-PD-1,
             anti-PD-L1, anti-PD-L2, anti-CTLA4 antibody, or any other antibody or drug
             specifically targeting T-cell costimulation or immune checkpoint pathways

          -  History of allergies and Adverse Drug Reaction:

               -  Hypersensitivity to human albumin, TIL excipient

               -  Hypersensitivity to Nivolumab or related excipients

               -  History of severe hypersensitivity reaction to any monoclonal antibody

               -  Hypersensitivity to aldesleukin or to one of Proleukin excipients

          -  History of chronic autoimmune disease (Addison's disease, multiple sclerosis, Graves'
             disease, rheumatoid arthritis, systemic lupus erythematosus, etc…) except patient with
             active vitiligo or a history of vitiligo.

          -  History of uveitis or melanoma-associated retinopathy

          -  History of inflammatory bowel disease, celiac disease, or other chronic
             gastrointestinal conditions associated with diarrhea.

          -  Presence of a second active cancer, with the exception of an in situ cervical cancer
             or a skin cancer different from the treated melanoma

          -  Unchecked thyroid dysfunction

          -  Any serious, acute or chronic illness id est active infection asking for antibiotics
             administration, coagulation's disorders, or any state asking for an unauthorized
             concomitant treatment described in this study

          -  Patients should be excluded if they have a condition requiring systemic treatment with
             either corticosteroids (> 10 mg daily prednisone equivalents) or other
             immunosuppressive medications within 14 days before study drug administration. Inhaled
             or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents
             are permitted in the absence of active autoimmune disease. Subjects are permitted to
             use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids
             (with minimal systemic absorption). Physiologic replacement doses of systemic
             corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief
             course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment
             of nonautoimmune conditions (eg, delayed-type hypersensitivity reaction caused by
             contact allergen) is permitted.

          -  Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de
             justice")

        Exclusion Criteria:

        * Positive viral serology for HIV (human immunodeficiency virus) 1/2, p24 Ag, HTLV1, HTLV2,
        B and C hepatitis or syphilis